Education
About Us
Working with TipRanks
Follow Us
IceCure Medical (ICCM)
NASDAQ:ICCM
ICCM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.47 - $1.63
Previous CloseN/A
Volume318.06K
Average Volume (3M)1.60M
Market Cap
$68.21M
Enterprise Value$55.42M
Total Cash (Recent Filing)$5.38M
Total Debt (Recent Filing)$2.37M
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
Nov 25, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding68,693,054
10 Day Avg. Volume2,910,625
30 Day Avg. Volume1,604,348
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue19.89
Enterprise Value/Gross Profit55.36
Enterprise Value/Ebitda-3.57
Forecast
1Y Price Target
$2.19Price Target Upside123.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Financial PerformanceICCM's recent rights offering was 2x oversubscribed, generating significant gross proceeds that will support its financial stability.
Market PotentialGrowing traction in European markets, supported by positive clinical data, indicates strong potential for international expansion.
Regulatory ApprovalCompany is on track for FDA approval of ProSense for early-stage breast cancer, which could significantly boost its market presence.
Bears Say
Capital NeedsThe company may need to raise additional capital within the next 12 months due to its current cash position and cash flows from operating activities.
Operational ChallengesShipments of product sales worth more than $200K were delayed due to the Israel-Iran conflict.
Revenue DeclineRevenue was $525K, representing 48% YoY decline and missing our projection of $800K.
Icecure Medical News
ICCM FAQ
What was IceCure Medical’s price range in the past 12 months?
IceCure Medical lowest stock price was $0.47 and its highest was $1.63 in the past 12 months.
What is IceCure Medical’s market cap?
IceCure Medical’s market cap is $68.21M.
When is IceCure Medical’s upcoming earnings report date?
IceCure Medical’s upcoming earnings report date is Nov 25, 2025 which is in 72 days.
How were IceCure Medical’s earnings last quarter?
IceCure Medical released its earnings results on Aug 13, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.064 by $0.004.
Is IceCure Medical overvalued?
According to Wall Street analysts IceCure Medical’s price is currently Undervalued.
Does IceCure Medical pay dividends?
IceCure Medical does not currently pay dividends.
What is IceCure Medical’s EPS estimate?
IceCure Medical’s EPS estimate is -0.06.
How many shares outstanding does IceCure Medical have?
IceCure Medical has 68,693,054 shares outstanding.
What happened to IceCure Medical’s price movement after its last earnings report?
IceCure Medical reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.064. Following the earnings report the stock price went up 2.439%.
Which hedge fund is a major shareholder of IceCure Medical?
Currently, no hedge funds are holding shares in ICCM
Icecure Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.19 (123.47% Upside)
$2.19 (123.47% Upside)
Blogger Sentiment
Bullish
ICCM Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 11.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 32.8%
Last 30 Days ▲ 32.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
59.38%
12-Months-Change
Fundamentals
Return on Equity
-230.80%
Trailing 12-Months
Asset Growth
-31.06%
Trailing 12-Months
Company Description
IceCure Medical
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
ICCM Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights strong regulatory progress and clinical achievements, particularly with ProSense's anticipated FDA approval and significant adoption in Europe and Japan. However, these positives are tempered by financial challenges, including decreased revenue, gross profit, and continued net losses, partly due to geopolitical issues.View all ICCM earnings summariesICCM Stock 12 Month Forecast
Average Price Target
$2.19
▲(123.47% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.06% Mutual Funds
0.12% Other Institutional Investors
99.82% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---